The Chemical Screening and Optimization Facility (CSOF) fulfills a unique role by identifying, optimizing and conducting production identified small molecules for contraceptive and reproductive health related (e.g., infertility, polycystic ovarian syndrome, fibroids, endometriosis, dysmenorrhea, adenomyosis, gynecologic and/or pelvic pain, and vulvodynia, premature birth, placenta health, improving lactation quality and quantity, preeclampsia, perinatal microbiome, gestational diabetes, inflammation, bacterial infections, viral infections, necrotizing enterocolitis, bronchopulmonary dyplasia, pre-term birth, fetal growth restriction, mastitis, Cushing's disease, Down Syndrome, Ricketts, Muscular Dystrophy, Rett syndrome, sepsis, or Autism) research. One approach is to conduct scalable quantity projects of identified small molecule(s) (e.g., natural product) and/or large molecule (e.g., polymer) that afford a contraceptive effect against a validated target or as a treatment for an identified reproductive health related indication. The research contained within this task order will encompass generation and purification of small or large molecules where purity of the final product shall be verified using methods including, but not limited to, Proton-Nuclear Magnetic Resonance (1H-NMR), Carbon-13-Nuclear Magnetic Resonance (C-NMR), Liquid Chromatography–Mass Spectrometry (LC-MS), High-Performance Liquid Chromatography (HPLC), Infrared (IR) Spectroscopy, melting point.